Sexual function in Chinese women with different clinical phenotypes of polycystic ovary syndrome

Figures & data

Table 1. Clinical characteristics in patients with four PCOS phenotypes and control women.

	Control	Phenotype A	Phenotype B	Phenotype C	Phenotype D	P value
N (%)	385	408 (50.43)	114 (14.09)	73 (9.02)	214 (26.45)
Age (years)	27.56 ± 3.83	26.89 ± 3.95	27.47 ± 3.88	28.17 ± 4.38	27.87 ± 3.91	0.181
BMI (kg/m^2)	23.35 ± 3.53^a^bc	26.78 ± 3.89^d	25.77 ± 4.42^d	25.06 ± 3.53	23.24 ± 3.70	<0.01
WC (cm)	79.10 ± 10.47^a^b	87.45 ± 12.44^c^d	86.09 ± 10.81^d	83.86 ± 10.62	83.39 ± 11.23	<0.001
F-G score	1.23 ± 0.51^a^bcd	3.15 ± 1.42 ^c^d	3.15 ± 1.38^d	2.75 ± 1.46	1.77 ± 0.77	<0.05
LH/FSH	1.11 ± 0.16^a^bcd	2.24 ± 0.48^d	2.18 ± 0.88^d	2.19 ± 0.61^d	1.95 ± 0.44	<0.001
TT (nmol/L)	0.92 ± 0.14^a^bcd	2.62 ± 0.49^b^cd	2.47 ± 0.59^c^d	2.09 ± 0.59^d	1.39 ± 0.41	<0.01
SHBG (nmol/L)	57.89 ± 42.67^a^bcd	30.21 ± 26.22^d	30.34 ± 25.79^d	34.22 ± 29.03^d	47.65 ± 34.02	<0.01
Bio-T (pg/ml)	73.45 ± 52.12^a^bcd	186.49 ± 111.19^c^d	179.42 ± 102.64^c^d	143.66 ± 107.43	142.92 ± 78.11	<0.001
DHEAS (ng/ml)	1201.33 ± 573.19^a^bcd	2792.57 ± 899.65^c^d	2682.11 ± 935.32^c^d	2200.12 ± 877.68	2039.71 ± 745.41	<0.05
17-OHP (ng/ml)	0.74 ± 0.55	0.92 ± 0.62	0.89 ± 0.47	0.72 ± 0.49	0.81 ± 0.51	0.271
HOMA-IR	1.46 ± 0.64^a^bc	2.61 ± 0.78^c^d	2.52 ± 0.92^c^d	2.17 ± 0.61	1.93 ± 0.55	<0.001
Infertility [n (%)]^#	0 (0)	346 (84.80)^c^d	94 (82.46)^c^d	43 (58.90)	134 (62.62)	<0.001
Infertility treatment  [n (%)]^#	0 (0)	179 (43.87)^c^d	48 (42.11)^c^d	11 (15.07)	31 (14.49)	<0.001

PCOS: polycystic ovary syndrome; BMI, body mass index; WC, waist circumference; F-G score, Ferriman and Gallwey score; LH/FSH, luteinizing hormone/follicle-stimulating hormone; TT, total testosterone; SHBG, sex hormone-binding globulin; Bio-T, bioavailable testosterone; DHEAS, dehydroepiandrosterone sulfate; 17-OHP, 17-hydroxyprogesterone; HOMA-IR, homeostasis model assessment for insulin resistance index;.

P values refer to the Kruskal-Wallis test.

^# Values are given as number (%) by using Chi-square test.

^a P < 0.05 compared with phenotype A;

^b P < 0.05 compared with phenotype B;

^c P < 0.05 compared with phenotype C;

^d P < 0.05 compared with phenotype D.

Table 2. SF-12 scores in patients with four PCOS phenotypes and control women.

	Control	Phenotype A	Phenotype B	Phenotype C	Phenotype D	P value
N (%)	385	408 (50.43)	114 (14.09)	73 (9.02)	214 (26.45)
MCS	54.32 ± 19.82^a^b	47.67 ± 16.54^c	49.33 ± 17.21^c	53.07 ± 16.34	52.15 ± 20.18	<0.05
PCS	51.17 ± 21.38	46.49 ± 17.66	46.51 ± 15.49	49.22 ± 16.72	49.53 ± 18.81	0.057

SF-12, the 12-item short form health survey; PCOS: polycystic ovary syndrome; MCS: mental component summary; PCS: physical component summary.

P values refer to the Kruskal-Wallis test.

^a P < 0.05 compared with phenotype A;

^b P < 0.05 compared with phenotype B;

^c P < 0.05 compared with phenotype C.

Table 3. FSFI scores and proportion of participants with FSFI score < 26.55 in patients with four PCOS phenotypes and control women (n = 809).

	Control	Phenotype A	Phenotype B	Phenotype C	Phenotype D	P value
N (%)	385	408 (50.43)	114 (14.09)	73 (9.02)	214 (26.45)
Total FSFI Score	24.98 ± 3.78^a^b	23.14 ± 3.22^d	24.15 ± 1.97	24.33 ± 2.33	24.47 ± 2.57	<0.01
Desire	3.81 ± 0.85^a^b	3.21 ± 0.91^c^d	3.56 ± 0.79^d	3.68 ± 0.74	3.72 ± 0.72	<0.05
Arousal	3.99 ± 1.02	3.80 ± 0.93	3.84 ± 0.86	3.88 ± 0.81	3.79 ± 0.92	0.292
Lubrication	4.58 ± 1.17^a^c	4.38 ± 1.21^b^cd	4.57 ± 0.93	4.51 ± 1.08	4.56 ± 1.15	<0.05
Orgasm	4.03 ± 0.93^a	3.70 ± 0.74^d	3.85 ± 0.89^d	3.92 ± 0.92	3.96 ± 0.86	<0.05
Satisfaction	4.54 ± 1.27^a^bcd	4.00 ± 1.02^d	4.35 ± 1.15	4.40 ± 1.12	4.47 ± 1.08	<0.001
Pain	4.01 ± 0.89	3.98 ± 1.13	3.98 ± 0.87	3.96 ± 0.93	3.97 ± 1.04	0.147
Number at risk of sexual dysfunction	236	357	94	55	151
Percentage at risk of sexual dysfunction ^#	61.30%^a^bc	87.5%^c^d	82.46%^c^d	75.34%	70.56%	<0.05

FSFI: Female Sexual Function Index. PCOS: polycystic ovary syndrome.

P values refer to ANOVA.

^# Values are given as number (%) by using Chi-square test..

^a P < 0.05 compared with phenotype A;

^b P < 0.05 compared with phenotype B;

^c P < 0.05 compared with phenotype C;

^d P < 0.05 compared with phenotype D.

Table 4. Risk factors for FSD analyzed by multivariate linear regression analysis.

Variable	Standardized coefficients	Standard error	P value
Infertility treatment	−0.387	0.18	0.007
Bio-T	−0.27	0.023	<0.001
MCS	0.057	0.01	<0.001
Age	−0.046	0.013	0.000
WC	−0.001	0	<0.001

FSD, female sexual dysfunction; Bio-T, bioavailable testosterone; MCS: mental component summary; WC, waist circumference.

Data availability statement

The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.